NAYA Biosciences Inc
NASDAQ:NAYA
NAYA Biosciences Inc
Common Shares Outstanding
NAYA Biosciences Inc
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NAYA Biosciences Inc
NASDAQ:NAYA
|
Common Shares Outstanding
$3.9m
|
CAGR 3-Years
96%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Common Shares Outstanding
$290m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Common Shares Outstanding
$1.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
Stryker Corp
NYSE:SYK
|
Common Shares Outstanding
$381.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Common Shares Outstanding
$1.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Common Shares Outstanding
$356.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
NAYA Biosciences Inc
Glance View
INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
See Also
What is NAYA Biosciences Inc's Common Shares Outstanding?
Common Shares Outstanding
3.9m
USD
Based on the financial report for Sep 30, 2024, NAYA Biosciences Inc's Common Shares Outstanding amounts to 3.9m USD.
What is NAYA Biosciences Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
75%
Over the last year, the Common Shares Outstanding growth was 58%. The average annual Common Shares Outstanding growth rates for NAYA Biosciences Inc have been 96% over the past three years , 75% over the past five years .
You don't have any saved screeners yet